$95.05
1.43% today
NYSE, Nov 19, 10:10 pm CET
ISIN
US58933Y1055
Symbol
MRK

Merck & Co. Stock price

$96.43
+10.11 11.71% 1M
+19.20 24.86% 6M
-3.05 3.07% YTD
-0.13 0.13% 1Y
-7.80 7.48% 3Y
+19.91 26.02% 5Y
+44.72 86.48% 10Y
+67.42 232.45% 20Y
NYSE, Closing price Tue, Nov 18 2025
+3.57 3.84%

New AI Insights on Merck & Co. Insights AI Insights on Merck & Co.

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$239.3b
Enterprise Value
$262.5b
Net debt
$23.2b
Cash
$18.2b
Shares outstanding
2.5b
Valuation (TTM | estimate)
P/E
12.7 | 10.7
P/S
3.7 | 3.7
EV/Sales
4.1 | 4.0
EV/FCF
20.1
P/B
4.6
Dividends
DPS
$3.12
Yield 1Y | 5Y
3.2% | 3.0%
Growth 1Y | 5Y
5.4% | 7.7%
Payout 1Y | 3Y
46.3% | 70.5%
Increased
14 Years
Financials (TTM | estimate)
Revenue
$64.2b | $65.3b
EBITDA
$29.0b | $30.4b
EBIT
$24.5b | $27.3b
Net Income
$19.0b | $22.5b
Free Cash Flow
$13.0b
Growth (TTM | estimate)
Revenue
1.7% | 1.8%
EBITDA
3.4% | 5.5%
EBIT
2.8% | 12.2%
Net Income
56.7% | 31.2%
Free Cash Flow
-12.1%
Margin (TTM | estimate)
Gross
78.7%
EBITDA
45.2% | 46.5%
EBIT
38.1%
Net
29.6% | 34.4%
Free Cash Flow
20.3%
Financial Health
Equity Ratio
39.6%
Return on Equity
37.0%
ROCE
24.2%
ROIC
21.3%
Debt/Equity
0.8
More
EPS
$7.6
FCF per Share
$5.2
Short interest
1.2%
Employees
74k
Rev per Employee
$870.0k
Show more

Create a Free Account to create an Merck & Co. alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Merck & Co. Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a Merck & Co. forecast:

19x Buy
58%
14x Hold
42%

Analyst Opinions

33 Analysts have issued a Merck & Co. forecast:

Buy
58%
Hold
42%

Financial data from Merck & Co.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
64,235 64,235
2% 2%
100%
- Direct Costs 13,671 13,671
8% 8%
21%
50,564 50,564
4% 4%
79%
- Selling and Administrative Expenses 10,647 10,647
0% 0%
17%
- Research and Development Expense 15,459 15,459
11% 11%
24%
29,027 29,027
3% 3%
45%
- Depreciation and Amortization 4,569 4,569
7% 7%
7%
EBIT (Operating Income) EBIT 24,458 24,458
3% 3%
38%
Net Profit 19,034 19,034
57% 57%
30%

In millions USD.

Don't miss a Thing! We will send you all news about Merck & Co. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Merck & Co. Stock News

Positive
Forbes
about 4 hours ago
In this week's edition of InnovationRx, we look at the biotech deal frenzy, Recursion's incoming CEO, the infant formula botulism outbreak, and more. To get it in your inbox, subscribe here.
Positive
MarketBeat
about 9 hours ago
Is the artificial intelligence revolution hitting its first roadblock? For the first time since the AI boom began in 2023, the industry is starting to feel the weight of expectations, and many of the tech sector's biggest winners have been struggling amidst a volatile market.
Positive
Reuters
about 10 hours ago
Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial.
More Merck & Co. News

Company Profile

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Head office United States
CEO Robert Davis
Employees 74,000
Founded 1891
Website www.merck.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today